Overview Performance Dividends Peer Group Options

(AMRN) Amarin - Ratings and Ratios

Exchange: NASDAQ • Country: Ireland • Currency: USD • Type: Common Stock • ISIN: US0231112063

AMRN: Omega-3, Fatty Acids, Cardiovascular, Pharmaceuticals

Amarin Corporation plc (NASDAQ:AMRN) is a biopharmaceutical company focused on developing and commercializing innovative therapeutics to address cardiovascular diseases. Its lead product, VASCEPA (icosapent ethyl), is an FDA-approved prescription-only omega-3 fatty acid medication designed to reduce triglyceride levels in adults with severe hypertriglyceridemia. The drug has also gained approval for reducing cardiovascular risk in certain high-risk patients. Amarin operates primarily in the U.S., Europe, Canada, Lebanon, and the United Arab Emirates, distributing its products through wholesalers and specialty pharmacy providers. The company collaborates with Mochida Pharmaceutical Co., Ltd. to expand its product portfolio and indications. Originally incorporated in 1989 as Ethical Holdings plc, Amarin rebranded in 1999 and is headquartered in Dublin, Ireland.

Based on the current technical indicators, AMRN is trading below its 20-day and 50-day simple moving averages (SMA), which are at 0.57 and 0.54 respectively, while the 200-day SMA stands at 0.62. The stock is showing signs of short-term weakness, with the average trading volume of 910,989 shares over the past 20 days. The ATR of 0.04 indicates low volatility, suggesting that price movements are likely to remain tight in the near term. From a fundamental perspective, Amarins market cap is $242.32 million, with a forward P/E ratio of 500.00, reflecting high expectations for future earnings despite current losses (RoE: -7.41). The P/S ratio of 1.01 indicates moderate valuation relative to its revenue. Over the next three months, the stock is likely to face resistance at the 200-day SMA of 0.62 and support at the 50-day SMA of 0.54. The low ATR suggests limited price fluctuations, but the negative return on equity and high forward P/E ratio may weigh on investor sentiment.

Additional Sources for AMRN Stock

News: Wall Street Journal Benzinga Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

AMRN Stock Overview

Market Cap in USD 218m
Sector Healthcare
Industry Drug Manufacturers - General
GiC Sub-Industry Biotechnology
IPO / Inception 1993-04-01

AMRN Stock Ratings

Growth 5y -97.0%
Fundamental -44.1%
Dividend 0.0%
Rel. Strength Industry -45.5
Analysts 2.33/5
Fair Price Momentum 0.20 USD
Fair Price DCF 0.19 USD

AMRN Dividends

No Dividends Paid

AMRN Growth Ratios

Growth Correlation 3m 27.9%
Growth Correlation 12m -90.1%
Growth Correlation 5y -95.8%
CAGR 5y -47.33%
CAGR/Max DD 5y -0.49
Sharpe Ratio 12m -1.19
Alpha -62.04
Beta 1.26
Volatility 96.45%
Current Volume 1456.7k
Average Volume 20d 908.3k
What is the price of AMRN stocks?
As of March 16, 2025, the stock is trading at USD 0.41 with a total of 1,456,668 shares traded.
Over the past week, the price has changed by -21.92%, over one month by -32.43%, over three months by -12.37% and over the past year by -49.65%.
Is Amarin a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Amarin (NASDAQ:AMRN) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -44.08 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AMRN as of March 2025 is 0.20. This means that AMRN is currently overvalued and has a potential downside of -51.22%.
Is AMRN a buy, sell or hold?
Amarin has received a consensus analysts rating of 2.33. Therefor, it is recommend to sell AMRN.
  • Strong Buy: 0
  • Buy: 0
  • Hold: 1
  • Sell: 2
  • Strong Sell: 0
What are the forecast for AMRN stock price target?
According to ValueRays Forecast Model, AMRN Amarin will be worth about 0.2 in March 2026. The stock is currently trading at 0.41. This means that the stock has a potential downside of -46.34%.
Issuer Forecast Upside
Wallstreet Target Price 1 143.9%
Analysts Target Price 1 143.9%
ValueRay Target Price 0.2 -46.3%